Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT02096666 2021-12-28

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Amgen

Phase 1/2 Completed
11 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡